Brivaracetam: Rationale for discovery and preclinical profile of a selective SV2A ligand for epilepsy treatment. - Wikidata - awgldk - TriplyDB

Brivaracetam: Rationale for discovery and preclinical profile of a selective SV2A ligand for epilepsy treatment.

Brivaracetam: Rationale for discovery and preclinical profile of a selective SV2A ligand for epilepsy treatment.

http://www.wikidata.org/entity/Q38752407

about

Synaptic Vesicle Glycoprotein 2A Ligands in the Treatment of Epilepsy and Beyond Brivaracetam as adjunctive therapy for the treatment of partial-onset seizures in patients with epilepsy: the current evidence base Analgesic, antiallodynic, and anticonvulsant activity of novel hybrid molecules derived from N-benzyl-2-(2,5-dioxopyrrolidin-1-yl)propanamide and 2-(2,5-dioxopyrrolidin-1-yl)butanamide in animal models of pain and epilepsy.Seizure control through genetic and pharmacological manipulation of Pumilio in Drosophila: a key component of neuronal homeostasis A Missense Mutation of the Gene Encoding Synaptic Vesicle Glycoprotein 2A (SV2A) Confers Seizure Susceptibility by Disrupting Amygdalar Synaptic GABA Release.The preclinical discovery and development of brivaracetam for the treatment of focal epilepsy.Evaluation of brivaracetam: a new drug to treat epilepsy.Pharmacological Treatment of Drug-Resistant Epilepsy in Adults: a Practical Guide.Computational approaches for innovative antiepileptic drug discovery.Brivaracetam: A Review in Partial-Onset (Focal) Seizures in Patients with Epilepsy.Progress report on new antiepileptic drugs: A summary of the Thirteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XIII).Will Brivaracetam Help My Patient? Only Time Will Tell.Acute and long-term effects of brivaracetam and brivaracetam-diazepam combinations in an experimental model of status epilepticus.Epilepsy Treatment: A Futurist View.Brivaracetam does not modulate ionotropic channels activated by glutamate, γ-aminobutyric acid, and glycine in hippocampal neurons.A resurging boom in new drugs for epilepsy and brain disorders.Evidence for a differential interaction of brivaracetam and levetiracetam with the synaptic vesicle 2A protein.Brivaracetam: a novel antiepileptic drug for focal-onset seizures.A review of the pharmacology and clinical efficacy of brivaracetam.An RNAi-mediated screen identifies novel targets for next-generation antiepileptic drugs based on increased expression of the homeostatic regulator pumilio.

P2860

Q28068507-AC6E28F0-7DC7-4480-AA8A-D4B7E211F784 Q28076065-F20F3F7D-515E-46EB-A5D9-FB9A66416BAE Q33621804-B68A8BE4-B293-4A7C-A16A-EDA603E9905C Q36244251-53B87637-1DAE-460B-8B60-F0C5B48C292D Q37092563-E988A6D7-B87A-4F25-8053-3FCB89121A96 Q38614499-D4F519E1-994F-404D-852B-2B6EA6B91A5B Q38652806-7A8E2B32-2F12-4116-9121-680733877FAB Q38904679-E98328C9-1215-4C2A-BE8A-41EE9E1750FA Q38907478-7D7687C9-4929-48F3-930E-46336CD49335 Q38922348-441381D3-9700-4844-B1A0-A4BEBB616C96 Q39006241-339D1503-49A8-4D6A-824E-BF2C8EB5BB92 Q42317849-7D720200-B737-4A21-AF9F-5376BDD57D18 Q46010938-188CF6BB-E447-4FB8-B1CB-EE1D8886CF63 Q47114432-AD90D5F9-1735-439B-9912-4ED425B5985B Q47888971-3E52476A-2061-422A-B796-19D662DC7416 Q48093388-F74A78C3-A4A4-446D-855A-3D9DD6CE7336 Q48383809-8B8643A1-C9F6-408E-BC98-CC50775E2A9E Q49253776-2AAAF0B9-0372-46BE-A39E-F52D80738371 Q49700507-8385C7AC-F3D7-4867-82DD-12A95A94BCDD Q52714753-059FA6E2-736F-486D-B4A9-A0238EA01EDB

P2860

Brivaracetam: Rationale for discovery and preclinical profile of a selective SV2A ligand for epilepsy treatment.

http://www.wikidata.org/entity/Q38752407

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Brivaracetam: Rationale for di ...... ligand for epilepsy treatment.

@en

type

label

Brivaracetam: Rationale for di ...... ligand for epilepsy treatment.

@en

prefLabel

Brivaracetam: Rationale for di ...... ligand for epilepsy treatment.

@en

P1433

Q38752407-F2CCBE70-3DEE-4956-A551-BE6157DA25EF

P1476

Q38752407-EC657619-4DAB-4EBE-B71E-BDB869D1A74E

P2093

Q38752407-3A9BFC20-6D6A-4AA1-B4B0-6AFB43223C32

Q38752407-47439C15-AFF7-469E-BEEB-44CF0DDE07D6

Q38752407-484FEB08-8DD0-4F6F-AA22-BB3CBA1E2ED8

Q38752407-4CE1EE7B-A702-45D4-92AE-69E5F74E5D2A

Q38752407-4E1AE6EE-C3A6-4DAA-A481-4443559F6B6B

Q38752407-5493F37B-8AA8-4F87-B7FA-7FD2CE769D16

Q38752407-57E86B44-14A7-40B6-A605-C49F48AAC033

Q38752407-806A8BDC-6A0F-46E5-89D1-AED569F76B5B

Q38752407-875D65F5-3491-42D0-82CF-C879B2CEC2C6

Q38752407-9999B25A-AA3C-451B-B576-375215F2F4D9

P2860

Q38752407-029CD198-EDA3-44CE-B439-0ECF716565D3

Q38752407-039DA90E-927C-4BE6-B7E9-4C3DC3BCD18E

Q38752407-06DE3830-D921-4503-A1E4-3DD39D24CDB3

Q38752407-0C909B45-5B21-4483-AD70-E4DC31B9C7E7

Q38752407-10DD2513-7491-4072-A433-F239ECF4B53E

Q38752407-116099CC-1547-4096-B36B-E71FC0DC0200

Q38752407-168F878F-5442-49AB-8A29-740F7E4E1437

Q38752407-1C69A27F-DA5F-490B-896E-E0770479B47B

Q38752407-1DCC434C-AC4A-44BB-98D3-9195E273FB1E

Q38752407-213EAFD4-572F-48D9-BAF7-D45AFBFC00F6

P304

Q38752407-2F28E13B-E199-46C4-910F-59328E0F3556

P31

Q38752407-0B669092-EF33-44CD-9594-A4CBF297F157

P356

Q38752407-1525B20B-941E-4007-81F6-278B5ACF576C

P433

Q38752407-47D05F65-D64C-4ABC-86BF-32E65D1E4585

P478

Q38752407-4252DA46-C96B-4988-BB79-5CC4E4DBEBC7

P577

Q38752407-C9BB5401-76E1-4621-AF9D-D038FE7BF641

P5875

Q38752407-A453B3FA-2EE0-44CD-8F5C-EA9F3368454E

P698

Q38752407-75654C72-B2C3-4B11-A67D-E0D42305ACBC

P921

Q38752407-F9259BCB-E112-4A9E-B5B6-9A8F860AAEC8

P356

P1433

P1476

Brivaracetam: Rationale for di ...... ligand for epilepsy treatment.

@en

P2093

Alain Matagne

http://www.w3.org/2001/XMLSchema#string

Benoit Kenda

http://www.w3.org/2001/XMLSchema#string

Christian Wolff

http://www.w3.org/2001/XMLSchema#string

Henrik Klitgaard

http://www.w3.org/2001/XMLSchema#string

Isabelle Niespodziany

http://www.w3.org/2001/XMLSchema#string

Jean-Marie Nicolas

http://www.w3.org/2001/XMLSchema#string

Jonas Hannestad

http://www.w3.org/2001/XMLSchema#string

Karine Leclercq

http://www.w3.org/2001/XMLSchema#string

Marc De Ryck

http://www.w3.org/2001/XMLSchema#string

Martyn Wood

http://www.w3.org/2001/XMLSchema#string

P2860

The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam

Abnormal neurotransmission in mice lacking synaptic vesicle protein 2A (SV2A)

The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an unblinded randomised controlled trial

Early identification of refractory epilepsy

Selective blockade of N-type calcium channels by levetiracetam

Pharmacokinetics and metabolism of 14C-brivaracetam, a novel SV2A ligand, in healthy subjects

Intracellular calcium increase in epileptiform activity: modulation by levetiracetam and lamotrigine

The pharmacokinetics, CNS pharmacodynamics and adverse event profile of brivaracetam after multiple increasing oral doses in healthy men

Anti-convulsive and anti-epileptic properties of brivaracetam (ucb 34714), a high-affinity ligand for the synaptic vesicle protein, SV2A.

Modulation of the conformational state of the SV2A protein by an allosteric mechanism as evidenced by ligand binding assays.

P304

538-548

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/EPI.13340

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

57

http://www.w3.org/2001/XMLSchema#string

P577

2016-02-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

296193800

http://www.w3.org/2001/XMLSchema#string

P698

26920914

http://www.w3.org/2001/XMLSchema#string

P921